Results for Q1 2019
Results the first three months of fiscal year 2019 were announced on May 16. Conference call details
Applying our peptide platform to specialty disease areas to invent novel therapies.
Advancing fully owned development programs with Phase 3 in two rare disease programs. See our pipeline